Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.
Erika RijavecFederica BielloAlice IndiniFrancesco GrossiCarlo GenovaPublished in: Clinical pharmacology : advances and applications (2022)
Rearrangement of anaplastic lymphoma kinase ( ALK ) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a few years due to acquired resistance. Brigatinib is a second-generation ALK inhibitor effective in presence of several ALK mutations with demonstrated activity against central nervous system metastases. Currently, brigatinib is approved to treat ALK-positive metastatic NSCLC patients not previously treated with ALK inhibitors and patients who have progressed on or are intolerant to crizotinib. In this review, we provide a summary of results from clinical trials involving brigatinib, and we discuss its possible role in the management of ALK-positive NSCLC in the following years.
Keyphrases
- end stage renal disease
- newly diagnosed
- small cell lung cancer
- advanced non small cell lung cancer
- ejection fraction
- chronic kidney disease
- clinical trial
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- gene expression
- dna methylation
- patient reported outcomes
- genome wide
- epidermal growth factor receptor
- patient reported
- smoking cessation
- tyrosine kinase
- double blind